AstraZeneca rockets toward Tagrisso sales target with another survival win

9th August 2019 Uncategorised 0

AstraZeneca already has a Tagrisso approval for patients with previously untreated, EGFR-mutated lung cancer—and it’s already steamrolling, sales-wise. Now it’s shoring up its case with some clutch new data showing the targeted drug actually helps patients live longer.

More: AstraZeneca rockets toward Tagrisso sales target with another survival win
Source: fierce